DrugBiological
Velaglucerase alfa clinical trials
Also written VPRIV and GA-GCB.
- studies test it
- 13
- open now
- 0
- in phase 3
- 7
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 7
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 3
Shire (9) · Shaare Zedek Medical Center (2) · Takeda (1) · Baylor Research Institute (1)
Studies
Open first, then newest update. How each study uses velaglucerase alfa is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedPhase 3TakedaNCT05529992Written as Velaglucerase Alfa
- Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)CompletedPhase 4Shaare Zedek Medical CenterNCT04120506Written as VPRIV
- Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher DiseaseCompletedPhase 4ShireNCT02574286Written as Velaglucerase alfa
- A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher DiseaseCompletedPhase 3ShireNCT00430625Written as VPRIV ®,
- Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher DiseaseCompletedPhase 3ShireNCT01614574Written as velaglucerase alfa
- Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)CompletedPhase 1/2ShireNCT00391625Written as GA-GCB
- Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher DiseaseCompletedPhase 3ShireNCT01842841Written as velaglucerase alfa
- Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher DiseaseCompletedPhase 1/2ShireNCT01685216Written as velaglucerase alfa
- An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher DiseaseCompletedPhase 3ShireNCT00635427Written as VPRIV®
- Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With ImigluceraseCompletedPhase 2/3ShireNCT00478647Written as GA-GCB (velaglucerase alfa)
- Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher DiseaseCompletedPhase 3ShireNCT00553631Written as velaglucerase alfa
- Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher DiseaseCompletedPhase 4Shaare Zedek Medical CenterNCT03702361Written as VPRIV
- The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher DiseaseWithdrawnPhase 4Baylor Research InstituteNCT02528617Written as Velaglucerase alfa
Codes
What other systems call velaglucerase alfa · ClinicalTrials.gg INT014405
- UNII (FDA) 23HYE36B0IVELAGLUCERASE ALFAConfirmed FDA, Wikidata
- RxNorm 901805Confirmed FDA, Wikidata
- Wikidata Q3492447velaglucerase alfaConfirmed FDA, Wikidata
- NCI Thesaurus C87735Velaglucerase AlfaConfirmed FDA, Wikidata
- DrugBank DB06720One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 23HYE36B0I | VELAGLUCERASE ALFA | Confirmed FDA, Wikidata |
| RxNorm | 901805 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3492447 | velaglucerase alfa | Confirmed FDA, Wikidata |
| NCI Thesaurus | C87735 | Velaglucerase Alfa | Confirmed FDA, Wikidata |
| DrugBank | DB06720 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.